HC Wainwright Has Pessimistic Opinion of PLX Q4 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities researchers at HC Wainwright cut their Q4 2026 earnings estimates for Protalix BioTherapeutics in a report issued on Wednesday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.04) per share for the quarter, down from their previous estimate of $0.01. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q2 2027 earnings at $0.02 EPS, Q3 2027 earnings at $0.13 EPS and FY2027 earnings at $0.19 EPS.

Protalix BioTherapeutics Stock Down 5.4%

NYSE PLX opened at $2.96 on Friday. The company has a market cap of $238.49 million, a price-to-earnings ratio of -22.77 and a beta of 0.01. Protalix BioTherapeutics has a twelve month low of $1.65 and a twelve month high of $3.19. The business’s fifty day moving average is $2.68 and its 200 day moving average is $2.44.

Hedge Funds Weigh In On Protalix BioTherapeutics

Several large investors have recently bought and sold shares of PLX. BlackRock Inc. bought a new position in Protalix BioTherapeutics in the second quarter valued at about $9,429,000. Dimensional Fund Advisors LP grew its holdings in shares of Protalix BioTherapeutics by 932.7% during the first quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock worth $644,000 after purchasing an additional 268,099 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Protalix BioTherapeutics by 903.7% during the third quarter. Russell Investments Group Ltd. now owns 248,557 shares of the company’s stock worth $686,000 after purchasing an additional 223,792 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Protalix BioTherapeutics in the second quarter valued at approximately $543,000. Finally, Lazard Asset Management LLC increased its stake in shares of Protalix BioTherapeutics by 21.3% in the first quarter. Lazard Asset Management LLC now owns 86,617 shares of the company’s stock valued at $188,000 after buying an additional 15,224 shares during the period. 16.53% of the stock is currently owned by institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.